Literature DB >> 12772793

Correlation between histopathological findings of the liver and IgA class antibodies to 2-oxo-acid dehydrogenase complex in primary biliary cirrhosis.

Jun-Ichi Masuda1, Katsuhisa Omagari, Kazuo Ohba, Hiroaki Hazama, Yoshiko Kadokawa, Hideki Kinoshita, Kenji Hayashida, Kazuhiro Hayashida, Hiromi Ishibashi, Yasuni Nakanuma, Shigeru Kohno.   

Abstract

Although anti-mitochondrial antibody (AMA) is the characteristic serological feature of primary biliary cirrhosis (PBC), its pathogenetic role remains unclear. We tested sera from 72 Japanese patients with histologically confirmed PBC for AMA by indirect immunofluorescence, anti-pyruvate dehydrogenase complex (PDC) by enzyme inhibition assay, immunoglobulin (Ig) G class anti-PDC by ELISA, and IgG, IgM, and IgA class anti-2-oxo-acid dehydrogenase complex (2-OADC) by immunoblotting. Of the 72 sera, 60 (83%), 50 (69%), 42 (58%), and 71 (99%) were positive for AMA by immunofluorescence, enzyme inhibition assay, ELISA, and immunoblotting, respectively. There was no significant correlation between histological stages and AMA by immunofluorescence, PDC inhibitory antibodies by enzyme inhibition assay, IgG class anti-PDC antibodies by ELISA, or IgG and IgM class anti-2-OADC by immunoblotting. IgA class anti-2-OADC by immunoblotting was more frequent in stages 2-4 than in stage 1 (P = 0.0083). Of the IgA class anti-2-OADC, anti-PDC-E2 (74 kDa) and anti-E3BP (52 kDa) were more frequent in stages 2-4 than in stage 1 (P = 0.0253 and 0.0042, respectively). Further examination of histopathological findings in 53 of 72 liver biopsy specimens showed that IgA class anti-PDC-E2 and IgA class anti-E3BP were associated with bile duct loss, and IgA class anti-PDC-E2 was also associated with interface hepatitis and atypical ductular proliferation. IgA is known to be secreted into the bile through biliary epithelial cells, implying that IgA class anti-PDC-E2 and E3BP may have a specific pathogenetic role during their transport into the bile by binding to their target antigen(s) in biliary epithelial cells, and this may be followed by dysfunction and finally destruction of biliary epithelial cells. Our present results suggest that these autoantibodies against 2-OADC detected by immunoblotting may be associated with the pathogenesis and pathologic progression of PBC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12772793     DOI: 10.1023/a:1023055714208

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Mucosal IgA defect in primary biliary cirrhosis.

Authors:  Annarosa Floreani; Anna Baragiotta; Daniela Pizzuti; Diego Martines; Attilio Cecchetto; Silvia Chiarelli
Journal:  Am J Gastroenterol       Date:  2002-02       Impact factor: 10.864

2.  Natural history of early primary biliary cirrhosis.

Authors:  J V Metcalf; H C Mitchison; J M Palmer; D E Jones; M F Bassendine; O F James
Journal:  Lancet       Date:  1996-11-23       Impact factor: 79.321

Review 3.  Primary biliary cirrhosis.

Authors:  M M Kaplan
Journal:  N Engl J Med       Date:  1996-11-21       Impact factor: 91.245

4.  Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression.

Authors:  M D Van Norstrand; M Malinchoc; K D Lindor; T M Therneau; M E Gershwin; P S Leung; E R Dickson; H A Homburger
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

5.  Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis?

Authors:  C Corpechot; P Benlian; V Barbu; O Chazouillères; R E Poupon; R Poupon
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

6.  Purification of 2-oxo acid dehydrogenase multienzyme complexes from ox heart by a new method.

Authors:  C J Stanley; R N Perham
Journal:  Biochem J       Date:  1980-10-01       Impact factor: 3.857

Review 7.  Pathology and pathogenesis of intrahepatic bile duct loss.

Authors:  Y Nakanuma; K Tsuneyama; K Harada
Journal:  J Hepatobiliary Pancreat Surg       Date:  2001

8.  Studies on the relationships of IgA to human liver. IgA deposition in non-alcoholic liver diseases.

Authors:  H Nagura; Y Sumi; Y Fukuda; H Hasegawa; K Watanabe; W R Brown
Journal:  Acta Pathol Jpn       Date:  1989-06

9.  Characterization of recombinant monoclonal IgA anti-PDC-E2 autoantibodies derived from patients with PBC.

Authors:  Nobuyoshi Fukushima; Greg Nalbandian; Judy Van De Water; Kandra White; Aftab A Ansari; Patrick Leung; Thomas Kenny; Shizuo G Kamita; Bruce D Hammock; Ross L Coppel; Freida Stevenson; Hiromi Ishibashi; M Eric Gershwin
Journal:  Hepatology       Date:  2002-12       Impact factor: 17.425

10.  Clinical significance of positive immunoblotting but negative immunofluorescence for antimitochondrial antibodies in patients with liver diseases other than primary biliary cirrhosis.

Authors:  Jun-Ichi Masuda; Katsuhisa Omagar; Hiroshi Miyakawa; Hiroaki Hazama; Kazuo Ohba; Hideki Kinoshita; Isao Matsuo; Hajime Isomoto; Ikuo Murata; Shigeru Kohno
Journal:  Autoimmunity       Date:  2002-03       Impact factor: 2.815

View more
  3 in total

1.  Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments.

Authors:  Palak J Trivedi; Sue Cullen
Journal:  Hepatol Int       Date:  2012-03-20       Impact factor: 6.047

Review 2.  Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis.

Authors:  Takashi Himoto; Mikio Nishioka
Journal:  Auto Immun Highlights       Date:  2013-02-22

3.  Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis.

Authors:  Stella Gabeta; Gary L Norman; Christos Liaskos; Panagiotis A Papamichalis; Theodoros Zografos; Athanasios Garagounis; Eirini I Rigopoulou; George N Dalekos
Journal:  J Clin Immunol       Date:  2007-05-21       Impact factor: 8.542

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.